Contribution of Sales of New Products to Revenue Rises to 47.4% Driving Revenue Up by 16.4% Sino Biopharmaceutical Limited (Sino…
Search Results: Tot Biopharm (105)
By Accelerating New Drug Development and Employing New Online Platforms Sales of New Drugs Marketed over Past Three Years Double…
Seizes Opportunities from Industry Policies to Pursue Strategic Transformation Accelerates New Drug Development and Builds Internet Ecosystem Revenue from New…
RedHill Biopharma Ltd (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®,…
Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion Sino Biopharmaceutical Limited (“Sino Biopharm” or…
Revenue was approximately RMB6.22 Billion; Profit Attributable to Owners of the Parent was approximately RMB862 Million Sino Biopharmaceutical Limited (“Sino…
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new…
Revenue Climbs 16.0% to RMB24.23 billion Underlying Profit Up 10.2% to RMB3.13 billion; Achieves an outstanding R&D performance and obtains…
Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical…
Revenue Up 33.4% to RMB6,208 Million Underlying Profit* Climbs 22.4% to RMB976 Million Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the…
Revenue Up 41% to RMB20.9 Billion and Net Profit Climbs 317% to RMB9 Billion HONG KONG – (ACN Newswire) – Sino Biopharmaceutical Limited…
Profit Attributable to the Group Increased by Approximately 29.9% to Approximately RMB 2,247,477,000 HONG KONG – (ACN Newswire) – Sino Biopharmaceutical…
— NVK002 completed patient recruitment for both concurrent Phase III clinical trials significantly ahead of schedule — First commercialized product,…
HONG KONG — Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical…
The HKUST-Sino One Million Dollar Entrepreneurship Competition (referred to as HKUST Entrepreneurship Competition) Hong Kong Regional Final has successfully concluded,…
– and with 2024 1H Performance Growing Strongly – Everest Medicines Showcasing its Industry LeadershipRecently, Everest Medicines has announced another positive development.…
– With Efforts on the Development of New Quality Productive Forces Legend Holdings Corporation (Legend Holdings or the Company, HKG:…
On 28 August 2024, Fosun International (HKG: 0656) announced its 2024 interim results. During the reporting period, its revenue continued…
– Dorzagliatin (trade name: HuaTangNing, world’s first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic…
– Product Innovation + Model Innovation Achieves Remarkable Results to Create New Quality Productive Forces – Focuses on ‘AI +…